GlassScriptXultophy 100/3.6
Payments companies reported to CMS as associated with Xultophy 100/3.6. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xultophy 100/3.6, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xultophy 100/3.6
These are the largest totals companies reported as associated with Xultophy 100/3.6. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rosemarie Lajara | Plano, TX | Endocrinology, Diabetes & Metabolism | $20.81 |
| Qing Jia | Garland, TX | Endocrinology, Diabetes & Metabolism | $20.81 |
| Patricia Poleno | Allen Park, MI | Adult Health (Nurse Practitioner) | $14.12 |
| Subrahmanya Yellayi | Allen Park, MI | Cardiovascular Disease | $14.12 |
| Stacey Smick | Bridgeton, NJ | Physician Assistant | $13.89 |
| Celal Erbay | Gainesville, FL | Internal Medicine | $12.39 |
| Alexis Jones | Hamlin, WV | Family | $11.41 |
Prescribed Xultophy 100/3.6?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.